Bristol-Myers, Allied JV licenses immunoproteosome inhibitors from Cornell

Allied-Bristol Life Sciences formed ABLS IV, a new subsidiary which exclusively licensed immunoproteosome inhibitors from Weill Cornell Medical College and Cornell University to treat autoimmune and inflammatory diseases. ABLS IV will conduct and fund initial feasibility studies. Details were not disclosed...